|
From: Jason S. <js...@xe...> - 2026-06-30 17:47:38
|
Hi Support, Just following up on this request. Can I get confirmation that this is actively being worked on and a rough estimate when this questionnaire could be completed and returned? Thanks, Jason Samuel Sr. Cybersecurity Manager js...@xe...<mailto:js...@xe...> +1 (857) 420-8039 xenon-pharma.com<http://xenon-pharma.com/> | NASDAQ:XENE From: Jason Samuel Sent: June 18, 2026 12:23 PM To: su...@pr... Cc: Yura Zyuzin <yz...@xe...> Subject: Xenon 3rd party software review: ProteoWizard Hi Support, My name is Jason Samuel, and I'm a member of the cybersecurity governance team here at Xenon. We are currently evaluating ProteoWizard for use within our environment and, as part of our standard third-party risk management process, we ask all prospective vendors to complete a security questionnaire prior to engagement. I've attached the questionnaire to this email. Could you please have the appropriate member(s) of your team complete and return it by Friday, June 26? If you have any questions about specific items or need to share documentation under an NDA, I'm happy to coordinate. Please let me know who the best point of contact would be on your side for security and compliance matters and direct those questions there way. Thank you in advance. We appreciate your partnership in helping us maintain a strong security posture. Best, Jason Samuel Sr. Cybersecurity Manager js...@xe...<mailto:js...@xe...> +1 (857) 420-8039 xenon-pharma.com<http://xenon-pharma.com/> | NASDAQ:XENE Disclaimer The information contained in this communication from the sender is confidential and may be privileged. It is intended solely for use by the recipient and others authorized to receive it. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful. If you have received this email in error, please notify the sender immediately and destroy this email. |